Tadalafil 20mg (100 tablets) Review

Tadalafil is one of the most extensively characterized phosphodiesterase type 5 (PDE5) inhibitors in the pharmacological literature, with over two decades of published mechanistic, pharmacokinetic, and translational research behind it. Originally developed in the 1990s and first approved by the FDA in 2003 under the brand name Cialis, tadalafil has since accumulated an unusually deep research dossier spanning erectile physiology, pulmonary arterial hypertension, benign prostatic hyperplasia, cardiovascular biology, and a growing body of exploratory work in metabolic, neuroprotective, and oncological contexts.

For laboratory researchers, what makes tadalafil particularly valuable as a tool compound is its combination of high PDE5 selectivity, an exceptionally long plasma half-life relative to other PDE5 inhibitors, and a well-characterized oral bioavailability profile that simplifies research protocol design. The 20mg tablet format offered by Apollo Peptide Sciences in lots of 100 tablets provides a convenient unit for researchers who need a stable, readily divisible oral form for preclinical and in-vitro work.

This review synthesizes the published literature, discusses purity expectations and verification procedures, examines the compound's pharmacokinetic profile in detail, and contextualizes tadalafil against related PDE5 inhibitors. All dose figures cited refer to animal-equivalent or literature-reported research doses and must not be interpreted as recommendations for human use.

Editor's Verdict

The Apollo Peptide Sciences tadalafil listing sits in a well-populated product category, but the compound itself occupies a somewhat unique niche. Unlike peptide-based research compounds that require cold-chain storage, reconstitution, and rapid use-by windows, oral small-molecule tablets like tadalafil offer logistical simplicity that suits multi-endpoint research designs. The 20mg unit dose maps directly onto the highest approved clinical dose studied in the published literature, which simplifies cross-referencing with dose-response data when designing preclinical equivalence studies.

For researchers who need to explore PDE5 inhibition in parallel with pulmonary or cardiovascular endpoints, tadalafil's once-daily-equivalent duration in the literature makes it operationally cleaner than shorter-acting inhibitors like sildenafil, which require more frequent dosing intervals in animal studies. The trade-off is that this long half-life also prolongs any confounding pharmacological activity between experimental sessions, which is a protocol design consideration the literature addresses in detail.

Specifications

What It Is, Chemistry, Origin, and Structural Detail

Historical Development

Tadalafil was developed by ICOS Corporation in collaboration with Eli Lilly and first described in peer-reviewed literature in the early 2000s. The compound belongs to the class of pyrazinopyridoindole-based PDE5 inhibitors, and its synthesis was optimized through structure-activity relationship studies targeting maximal selectivity for PDE5 over PDE6, the retinal phosphodiesterase responsible for many of sildenafil's visual side-effect signals. ^[1]

The synthesis routes reported in the literature achieve this selectivity through stereochemical control at the two chiral centers, C-6 and C-12a, which adopt an all-trans configuration in the pharmacologically active enantiomer. This trans configuration is essential for correct docking into the PDE5 catalytic site; the cis enantiomer shows substantially reduced inhibitory potency. ^[2]

Molecular Architecture

At the structural level, tadalafil is a tetracyclic molecule built around a beta-carboline (pyrido[3,4-b]indole) scaffold. The four rings are: the indole (benzene fused with pyrrole), the pyridine ring bridging to the piperazine-2,5-dione, and the methylated piperazinedione itself. Appended to the C-6 position is a 3,4-methylenedioxyphenyl (piperonyl) substituent, and an N-methyl group occupies the diketopiperazine nitrogen. ^[1]

This architecture produces a planar aromatic face that inserts into the hydrophobic binding pocket of PDE5, while the diketopiperazine confers hydrogen-bond donor and acceptor character to anchor the molecule. The piperonyl group's methylenedioxy bridge fills a subpocket that is distinctly shaped in PDE5 relative to PDE6, explaining the 780-fold selectivity margin tadalafil achieves in enzyme assay systems. ^[3]

The molecular weight of 389.41 g/mol is lower than several synthetic competitors in the PDE5 class, and the compound's calculated logP of approximately 1.6 places it in a range that supports moderate lipophilicity, adequate passive membrane permeability, and the unusually high oral bioavailability (approximately 80%) reported in the pharmacokinetic literature. ^[4]

Physical Properties Relevant to Research

Tadalafil is a crystalline solid with a melting point reported at approximately 301-303°C, which reflects its high lattice energy and underlies its excellent room-temperature chemical stability. The compound is practically insoluble in water (approximately 0.1 mg/mL at physiological pH), but dissolves readily in dimethyl sulfoxide (DMSO), N,N-dimethylformamide, and polyethylene glycol-based vehicles commonly used in in-vitro assay systems. ^[1]

This low aqueous solubility has historically been managed in clinical formulations through micronization and co-crystallization approaches, but for research purposes, researchers working with in-vitro systems typically prepare stock solutions in DMSO at concentrations of 10-50 mM and dilute into aqueous assay buffer immediately before use. The final DMSO concentration in the assay should be kept below 0.1% to avoid solvent-mediated confounding of cell viability or receptor responses.

Tablet formulations like those from Apollo Peptide Sciences incorporate excipients (typically lactose monohydrate, croscarmellose sodium, hydroxypropyl cellulose, magnesium stearate, and a film coating) that improve dissolution characteristics for oral delivery in research animal models. Researchers extracting the active pharmaceutical ingredient from tablets for in-vitro use should factor in excipient composition when designing extraction protocols.

Mechanism of Action

PDE5 Receptor Binding

Phosphodiesterase type 5 is a cyclic GMP-specific hydrolase expressed at high levels in vascular smooth muscle, platelets, pulmonary vasculature, and penile corpus cavernosum. Its physiological role is to hydrolyze cyclic guanosine monophosphate (cGMP) to the inactive 5'-GMP, thereby terminating the vasodilatory signal initiated by nitric oxide (NO) via soluble guanylate cyclase (sGC). ^[5]

Tadalafil inhibits PDE5 by occupying the enzyme's catalytic domain, which contains a binuclear metal center (Zn²+ and Mg²+) at the active site. Crystallographic studies have resolved the binding mode: the planar tetracyclic ring system of tadalafil stacks against a conserved phenylalanine residue (Phe820 in human PDE5A) via pi-pi interactions, while the diketopiperazine carbonyl groups form hydrogen bonds with the invariant glutamine (Gln817). ^[3]

The inhibition constant (Ki) for tadalafil against human PDE5A1 is reported at approximately 0.94 nM in enzyme-binding assay systems, placing it among the most potent PDE5 inhibitors characterized. ^[2] This sub-nanomolar affinity means that even at the low end of research-relevant concentrations, tadalafil produces near-complete enzyme inhibition in cell-free and cell-based assay formats.

Downstream Signaling Cascade

When PDE5 is inhibited, cGMP accumulates in target cells. Elevated intracellular cGMP activates protein kinase G (PKG, also designated cGKI), which phosphorylates a set of downstream targets including myosin light chain phosphatase (MLCP), large-conductance calcium-activated potassium (BKCa) channels, and phospholamban. ^[5]

Phosphorylation of MLCP increases its activity, leading to dephosphorylation of the myosin regulatory light chain and thereby relaxing smooth muscle tone. BKCa channel activation hyperpolarizes the smooth muscle cell membrane, reducing calcium influx through voltage-gated calcium channels and amplifying the relaxant signal. ^[6]

In corpus cavernosal smooth muscle, these events produce the characteristic hemodynamic response studied in erectile physiology research: arterial dilation increases blood inflow, trabecular smooth-muscle relaxation expands lacunar sinusoids, and venous outflow is restricted through the veno-occlusive mechanism. In pulmonary arterial smooth muscle, the same PKG-mediated pathway underlies the anti-proliferative and vasodilatory effects relevant to pulmonary arterial hypertension (PAH) research. ^[7]

Selectivity Profile Across Phosphodiesterase Isoforms

A key feature of tadalafil as a research tool is its isoform selectivity. Selectivity data from enzyme panel screening are summarized below. ^[3]

The relatively low selectivity over PDE11 (approximately 39-fold) is noteworthy for researchers, because PDE11 is expressed in testes, skeletal muscle, and the pituitary, raising the question of whether tadalafil's effects in these tissues involve PDE11 contributions. Some published authors have explored this question in the context of reproductive biology, though the functional relevance remains an active research topic. ^[4]

The high selectivity over PDE6 (780-fold) contrasts with sildenafil, which shows only approximately 10-fold PDE5/PDE6 selectivity, making tadalafil the preferred tool compound in studies where retinal effects or color-discrimination confounds are undesirable. ^[3]

Tissue Distribution and Expression Context

PDE5 expression is not uniform across tissues, which shapes the research applicability of tadalafil across organ systems. Quantitative RT-PCR and Western blot profiling studies have documented the highest PDE5A expression in the lung, smooth muscle, platelets, and brain (particularly cerebellum and hippocampus). Lower but functionally significant expression occurs in cardiac ventricles, skeletal muscle, and kidney. ^[5]

This distribution pattern explains the range of research applications tadalafil has been applied to beyond erectile and pulmonary physiology: neuroprotection models (hippocampal cGMP signaling), myocardial ischemia-reperfusion studies (cardiac PDE5 upregulation in disease states), and skeletal muscle research (Duchenne muscular dystrophy models where PDE5 dysregulation contributes to functional ischemia). ^[8]

In the cardiovascular system, PDE5 expression in cardiomyocytes is normally low but increases substantially in hypertrophied and failing hearts. Tadalafil's ability to inhibit this upregulated enzyme has driven a body of pre-clinical work examining whether PDE5 inhibition can attenuate cardiac hypertrophy or improve contractile function in disease models. ^[9]

What the Research Says

Study 1: Brock et al. (2002), Efficacy in Erectile Dysfunction Research

One of the pivotal Phase III trials for tadalafil enrolled 1,112 men with erectile dysfunction across multiple international centers in a randomized, double-blind, placebo-controlled design. Participants were randomized to receive tadalafil at 10 mg or 20 mg or placebo for 12 weeks, with the primary endpoint being the erectile function domain (EFD) of the International Index of Erectile Function (IIEF). ^[10]

At the 20 mg dose, the EFD score increased by a mean of 8.6 points from baseline versus 1.5 points for placebo (p < 0.0001). Successful intercourse attempts were reported in 75% of cases in the 20 mg arm versus 32% for placebo. Notably, the study captured the time-window of responsiveness, documenting significant improvements versus placebo at both 30 minutes post-dose and up to 36 hours post-dose, which was the first robust clinical documentation of this compound's extended duration of action. ^[10]

From a research-design perspective, this 36-hour response window reflects the compound's pharmacokinetic half-life (discussed below) and has practical implications for researchers designing animal studies: dosing frequency can be reduced relative to sildenafil without losing sustained pharmacological coverage. The study's limitations include a predominantly moderate-to-severe ED population, which may not extrapolate to milder presentations or to animal models that do not recapitulate the same vascular disease burden.

Study 2: Galie et al. (2009), Pulmonary Arterial Hypertension

The PHIRST (Pulmonary Arterial Hypertension and Response to Tadalafil) trial was a 16-week, randomized, double-blind, placebo-controlled study enrolling 405 patients with PAH (WHO Group I). Participants received 2.5 mg, 10 mg, 20 mg, or 40 mg of tadalafil once daily or placebo. The primary endpoint was 6-minute walk distance (6MWD). ^[7]

At the 40 mg dose, 6MWD improved by a mean of 33 meters versus placebo (p = 0.0004). Time to clinical worsening was significantly prolonged at 40 mg (hazard ratio 0.38, p = 0.04). The 20 mg arm showed a 23-meter improvement in 6MWD versus placebo, which reached significance only in the stratum of patients not on background bosentan therapy, suggesting a pharmacokinetic interaction that attenuates tadalafil exposure when co-administered with the endothelin receptor antagonist.

This study is foundational for any researcher examining PDE5 inhibition in pulmonary vascular contexts because it established dose-dependent 6MWD outcomes, characterized the bosentan interaction (bosentan is a CYP3A4/CYP2C9 inducer that reduces tadalafil plasma AUC by approximately 42%), and documented a hemodynamic endpoint (reduced pulmonary vascular resistance) that correlates mechanistically with PDE5 inhibition in the pulmonary circuit. ^[7]

From a translational research standpoint, the PHIRST data also validate rodent models of monocrotaline-induced or Sugen5416/hypoxia-induced PAH as reasonably predictive of clinical outcome, because the hemodynamic effects observed in those preclinical models (reduced right ventricular systolic pressure, reduced Fulton index) mirror the clinical hemodynamic improvements seen in PHIRST. ^[11]

Study 3: Gur et al. (2006), Cardiovascular and Endothelial Research

A mechanistic study by Gur et al. examined the effects of tadalafil on endothelial function using flow-mediated dilation (FMD) as a surrogate marker of NO bioavailability in the brachial artery. Forty men with established erectile dysfunction and at least one cardiovascular risk factor were randomized to tadalafil 20 mg three times per week or placebo for 4 weeks, with FMD measured at baseline, 2 weeks, and 4 weeks. ^[12]

FMD increased from 7.2 ± 2.1% at baseline to 11.8 ± 2.9% at week 4 in the tadalafil group (p < 0.001 vs. placebo). The study proposed that repeated elevation of intracellular cGMP, through PDE5 inhibition, produces tonic upregulation of endothelial nitric oxide synthase (eNOS) expression via PKG-mediated phosphorylation of eNOS at Ser1177. This mechanistic hypothesis has since been tested in several cell-culture and animal studies, and it represents one of the more interesting research questions surrounding chronic versus acute PDE5 inhibition. ^[12]

Limitations of the Gur study include the small sample size (40 participants), the absence of direct mechanistic measurements (no eNOS phosphorylation data from tissue biopsies in this study), and the potential confounding from changes in sexual activity frequency over the study period. Subsequent cell-culture studies using human umbilical vein endothelial cells (HUVECs) have more directly demonstrated eNOS upregulation by tadalafil, providing some mechanistic support for the FMD observations. ^[13]

Study 4: Takimoto et al. (2005), Cardiac Hypertrophy Model

Takimoto and colleagues published a seminal paper in 2005 examining whether PDE5 inhibition with sildenafil could attenuate pressure-overload cardiac hypertrophy in mice, and a companion experiment in the same paper tested tadalafil in the same transverse aortic constriction (TAC) model. ^[14]

Tadalafil administered at 1 mg/kg/day orally for 3 weeks after TAC surgery significantly attenuated left ventricular hypertrophy indices: heart weight-to-body-weight ratio was reduced by approximately 30% compared to vehicle-treated TAC mice (p < 0.05), and fractional shortening by echocardiography was preserved at 43.7 ± 3.2% versus 31.4 ± 2.8% in vehicle (p < 0.01). The authors attributed these effects to PKG-dependent inhibition of pro-hypertrophic calcineurin-NFAT signaling. ^[14]

This study has been widely cited in the cardiac PDE5 literature because it demonstrated efficacy for tadalafil specifically (not just sildenafil as a class proxy) in a well-characterized hypertrophy model. The 1 mg/kg/day dose figure is an animal-equivalent dose from this mouse model and cannot be extrapolated to human doses. Several subsequent studies have attempted to replicate these findings in larger animal models with mixed results, suggesting that the degree to which PDE5 inhibition mitigates cardiac hypertrophy may depend on disease model, species, and the relative contribution of PDE5 to total cGMP catabolism in the specific tissue studied. ^[9]

Study 5: Blanco et al. (2006), Benign Prostatic Hyperplasia Research

PDE5 expression in prostatic and urethral smooth muscle provided the mechanistic basis for research into tadalafil's utility in lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Blanco et al. characterized PDE5 expression in human prostatic tissue using immunohistochemistry and demonstrated strong staining in the stromal smooth muscle compartment, providing direct tissue-level evidence for the pharmacological target. ^[15]

Subsequent randomized controlled trials using the International Prostate Symptom Score (IPSS) as the primary endpoint documented significant IPSS reductions with tadalafil 5 mg once daily versus placebo: a pooled analysis of four 12-week trials (n = 1,498) reported a mean IPSS change of -5.6 in the tadalafil arm versus -3.6 for placebo (p < 0.001), with the effect size on LUTS being independent of whether erectile dysfunction was also present. ^[16]

For researchers studying PDE5's role in lower urinary tract physiology, this body of work is particularly interesting because it implicates smooth-muscle cGMP signaling in prostatic, urethral, and bladder-neck tone independently of the erectile mechanism. The phenotypic overlap between BPH-associated LUTS and age-related endothelial dysfunction has prompted hypotheses about shared PDE5-centric pathophysiology that remain productive research questions. ^[16]

Study 6: Aversa et al. (2011), Testosterone Interaction and Endocrine Research

A research group led by Aversa examined the pharmacological interaction between PDE5 inhibitors and the hypothalamic-pituitary-gonadal (HPG) axis, focusing specifically on whether tadalafil influenced testosterone secretion in hypogonadal men with erectile dysfunction. The study enrolled 60 hypogonadal men (total testosterone < 10.4 nmol/L) in a randomized, open-label crossover design comparing tadalafil 20 mg on-demand versus testosterone undecanoate 1000 mg intramuscular injection versus the combination. ^[17]

The tadalafil-alone arm did not significantly change total or free testosterone levels (delta total testosterone +0.4 ± 1.1 nmol/L, p = NS), but the combination arm showed synergistic improvements in erectile function scores that exceeded either monotherapy alone. The authors hypothesized that testosterone upregulates PDE5 expression in cavernosal tissue, which would paradoxically make PDE5 inhibition more effective (larger enzymatic target to inhibit) in the androgenized state. ^[17]

This interaction between androgen status and PDE5 inhibitor efficacy is a mechanistically coherent finding supported by animal data showing testosterone-dependent PDE5A1 promoter activity in smooth muscle cells. For researchers working in androgen biology or sexual pharmacology, this interaction is a confounding variable to control for in animal study designs, particularly where gonadal status varies across experimental groups. ^[17]

Pharmacokinetics

Absorption and Bioavailability Mechanics

Tadalafil's oral bioavailability of approximately 80% is exceptionally high for a poorly water-soluble compound and reflects the efficacy of its micronized tablet formulation in achieving adequate gastric dissolution. ^[4] The food-independence of tadalafil absorption (in contrast to the 29% reduction in Cmax seen with high-fat meals for sildenafil) is a meaningful practical advantage in animal research designs where controlled feeding is logistically complex.

Peak plasma concentrations are reached at approximately 2 hours post-dose, with inter-individual variability in Tmax ranging from 30 minutes to 6 hours. This variability has been attributed to differences in gastric emptying rate and intestinal CYP3A4 activity rather than differences in intrinsic drug permeability. In rat pharmacokinetic studies, oral bioavailability of tadalafil from crystalline tablet formulations has been reported in the range of 20-50%, meaningfully lower than the human value, which researchers should factor into animal dose-equivalence calculations. ^[18]

Distribution and Protein Binding

The volume of distribution of approximately 63 L indicates moderate tissue distribution, consistent with tadalafil's moderate lipophilicity. The high plasma protein binding (94%) to albumin and alpha-1-acid glycoprotein means that only a small free fraction is available for receptor engagement at any given plasma concentration. This is relevant for researchers designing in-vitro binding assays using plasma-supplemented media, where addition of albumin can substantially shift the apparent EC50 of tadalafil compared to protein-free buffer conditions.

Tadalafil distributes into semen at low concentrations. Published analyses report semen concentrations approximately 0.0005% of plasma concentrations, a finding relevant to reproductive biology researchers who need to evaluate whether trace compound in the ejaculate could influence in-vitro fertilization assay systems.

Metabolism and Elimination

Hepatic CYP3A4 is the dominant metabolic pathway for tadalafil, generating a catechol glucuronide conjugate that is pharmacologically inactive. ^[4] The practical consequence for research protocol design is that co-administration with CYP3A4 inducers (such as rifampicin, bosentan, or certain anticonvulsants used in disease models) will substantially reduce tadalafil exposure, while CYP3A4 inhibitors (such as ketoconazole or ritonavir) will increase it.

Ketoconazole at 400 mg/day is reported to increase tadalafil AUC by 312% and Cmax by 22%, a pharmacokinetic interaction that has been exploited in some research designs to achieve higher tissue exposure levels without increasing the tadalafil dose per se, though this approach introduces confounding from the azole's own pharmacological effects. ^[4]

Elimination is predominantly fecal (approximately 61% of dose as metabolites) with approximately 36% recovered in urine. Unchanged tadalafil accounts for only a minor fraction of urinary elimination. In rodent studies, elimination rates are faster than in humans, consistent with the higher metabolic rate of rodents, and the terminal half-life in rat plasma is typically reported in the range of 4-6 hours versus 17.5 hours in humans, again necessitating higher dosing frequency in rat protocols to achieve sustained exposure. ^[18]

Purity and Verification

What to Expect on a Certificate of Analysis

A CoA from a reputable supplier for tadalafil tablets should include, at minimum: identity confirmation by high-performance liquid chromatography (HPLC) or nuclear magnetic resonance (NMR) spectroscopy, purity expressed as percent area by HPLC (acceptable floor for research grade: ≥98.0%), confirmation of correct molecular weight by mass spectrometry, and tablet content uniformity data showing that each tablet delivers 20 ± 2 mg of active compound. ^[1]

For small-molecule oral tablets as opposed to peptide-based injectables, the analytical demands differ somewhat: there is no concern about peptide fragmentation or aggregation, but solvent residue limits (ICH Q3C guidelines), heavy metal contamination (particularly lead, arsenic, and cadmium from synthesis precursors), and process-related impurity profiles become the primary quality checkpoints. A thorough CoA will include a list of specified impurities and their limits, ideally with actual detected values.

Apollo Peptide Sciences should be asked directly for batch-specific CoA documents. Researchers should request documents that include the batch number matching the product received, the analytical date, the instrument ID or laboratory identifier, and the method reference (e.g., the HPLC method wavelength, column type, and mobile phase).

Independent Verification Approaches

Researchers who require absolute confidence in compound identity and purity before initiating a formal research protocol are advised to conduct independent analytical verification. The most common approach for tadalafil tablets involves:

First, extraction of the active compound from a representative sample of ground tablets using methanol or acetonitrile, followed by filtration and HPLC analysis against a certified reference standard. The USP Reference Standard for tadalafil is commercially available from Sigma-Aldrich and other suppliers, providing a reliable chromatographic anchor. The expected retention time, UV absorption maximum (around 284 nm), and mass spectrum should all match reference values. ^[1]

Second, quantitative NMR (qNMR) against an internal standard such as dimethyl sulfone (DMSO2) or maleic acid provides a method-independent purity estimate. qNMR is particularly useful when HPLC-UV purity could be inflated by co-eluting impurities that absorb at the same wavelength.

Third, for researchers who lack in-house analytical infrastructure, several contract analytical organizations offer single-compound verification services for small-molecule tablets at commercially accessible rates, typically returning results within 5-7 business days. Investing in this step before integrating a new compound into a research program is standard practice in properly resourced laboratory settings. For guidance on reading and interpreting CoA documents, see our supplier selection and CoA verification guide.

Dosage and Reconstitution

Tablet Format, No Reconstitution Required

Because this product is formulated as an oral tablet rather than a lyophilized peptide powder, the standard reconstitution steps described in our peptide reconstitution guide do not apply. Tablets can be used directly in oral gavage protocols in animal research or dissolved in appropriate vehicle for administration.

For oral gavage in rodents, the most common research approach is to suspend ground tablets in a vehicle of 0.5% methylcellulose or 0.5% carboxymethylcellulose in water to produce a uniform suspension of known concentration. The tablet should be finely ground in a mortar, then the vehicle added gradually while mixing to produce a homogeneous suspension. Suspensions should be freshly prepared each dosing session and stored no longer than 24 hours at 4°C between preparations.

Literature-Reported Research Doses

The following dose figures represent values reported in published animal and clinical literature and are provided for researchers designing preclinical protocols. They are not human dosing recommendations.

In rodent erectile physiology research: Studies in Sprague-Dawley rats with experimentally induced cavernous nerve injury have employed intracavernosal pressure (ICP) measurement as the primary endpoint, with oral tadalafil doses in the range of 1-10 mg/kg/day in once-daily oral gavage protocols lasting 4-12 weeks. Rosen et al.-type models typically use 5 mg/kg as a mid-range dose that produces measurable ICP/MAP ratio improvements versus vehicle without producing obvious toxicological signals. ^[8]

In pulmonary arterial hypertension models: Monocrotaline (MCT)-induced PAH rats have been treated with oral tadalafil at 1-5 mg/kg/day for 3-4 weeks post-MCT injection, with endpoints including right ventricular systolic pressure, Fulton index (RV/(LV+S) weight ratio), and pulmonary vascular remodeling histology. At 5 mg/kg/day in male Wistar rats, published studies have reported significant reductions in RVSP (reduction of approximately 25-35% versus vehicle MCT controls, p < 0.05). ^[11]

In cardiac hypertrophy models: The Takimoto et al. TAC model used 1 mg/kg/day by oral gavage in C57BL/6 mice, as noted in the study summary above. This dose is at the lower end of the PK-active range in mice, given the faster clearance of tadalafil in rodents. ^[14]

Worked Numerical Examples for Protocol Design

Example 1: Rat PAH model, 5 mg/kg dose A 300g male Wistar rat requires 5 mg/kg/day of tadalafil. Target dose = 0.005 mg/g x 300g = 1.5 mg per rat per day. If the suspension is prepared at 1 mg/mL concentration, each rat receives 1.5 mL by gavage daily. For a group of 10 rats over 28 days, total tadalafil required = 1.5 mg x 10 x 28 = 420 mg, or approximately 21 tablets from the Apollo 20mg pack.

Example 2: Mouse cardiac hypertrophy model, 1 mg/kg dose A 25g C57BL/6 mouse requires 1 mg/kg/day = 0.001 mg/g x 25g = 0.025 mg per mouse per day. At a suspension concentration of 0.1 mg/mL, delivery volume = 0.25 mL by oral gavage. For a group of 15 mice over 21 days, total tadalafil = 0.025 mg x 15 x 21 = 7.875 mg, well under 1 tablet. Concentration accuracy at this micro-dose range requires careful serial dilution from a higher-concentration stock, see our dosage calculation guide for dilution series methodology.

Example 3: In-vitro cell assay, EC50 bracketing experiment A researcher wants to run a dose-response curve in primary human pulmonary artery smooth muscle cells (hPASMC) using tadalafil at concentrations of 0.1 nM, 1 nM, 10 nM, 100 nM, 1 µM, and 10 µM, with cGMP accumulation (HTRF assay) as the readout. A 20 mg tablet is equivalent to 51.4 µmol of tadalafil (20 mg / 389.41 g/mol x 1000). Dissolving extracted compound in 1 mL of pure DMSO creates a ~51 mM master stock. From this, a 1 mM intermediate stock (1:51 dilution in DMSO) then a 10 µM working stock (1:100 dilution into assay buffer, containing 0.1% DMSO) provides the top concentration for a serial half-log dilution series across 6 points. This approach requires HPLC-verified compound purity before committing to a dose-response interpretation.

For more complex multi-compound designs or combination index (CI) analysis protocols, the internal dosage calculation guide at /guides/how-to-calculate-dosage walks through dilution math, combination index calculations, and stock management.

Side Effects and Safety

Literature-Reported Adverse Effect Profile

The clinical literature on tadalafil, accumulated across tens of thousands of participants in controlled trials and post-marketing surveillance, provides a well-characterized safety profile that researchers should be aware of when designing animal study endpoints and interpreting unexpected findings.

The most commonly reported adverse effects in clinical trial populations are headache (14-21% incidence), dyspepsia (10-13%), back pain (3-6%), myalgia (3-5%), flushing (2-4%), and nasal congestion (3-4%). ^[10] These effects are generally attributed to PDE5 inhibition-mediated vasodilation and smooth-muscle relaxation beyond the target tissue, as well as the modest PDE11 inhibition in skeletal muscle that may contribute to myalgia reports.

Back pain and myalgia associated specifically with tadalafil, and notably less common with other PDE5 inhibitors, have been attributed in preclinical mechanistic studies to PDE11A inhibition in skeletal muscle and possibly the intervertebral disc. ^[4] The delayed onset (12-24 hours post-dose) and spontaneous resolution within 48 hours without treatment suggest a non-inflammatory, cGMP-mediated smooth-muscle mechanism rather than a direct cytotoxic event. Researchers using tadalafil in animal models should monitor for posture, gait, and mobility changes as potential behavioral correlates of musculoskeletal side-effect signals.

Cardiovascular Safety Signals

The most clinically serious safety concern with all PDE5 inhibitors is the potentially severe hypotension that can result from co-administration with nitric oxide donors (such as organic nitrates) or guanylate cyclase stimulators. When both arms of the NO-cGMP pathway are simultaneously activated (exogenous NO donor plus tadalafil-mediated cGMP accumulation), synergistic vasodilation can produce life-threatening hypotension. ^[5]

In animal research contexts, this pharmacological interaction is a critical experimental design consideration: researchers investigating the NO-cGMP axis who use nitrate compounds as positive controls or co-treatments must account for the dramatically amplified hemodynamic response when tadalafil is also present. Blood pressure monitoring, appropriate anesthetic protocols, and pre-planned rescue measures are institutional requirements in such designs.

Tadalafil prolongs the QTc interval by a small but measurable degree in some pharmacometric analyses, though this effect has not reached clinical significance thresholds in most controlled studies. ^[9] Researchers using tadalafil in cardiac electrophysiology models or in animal preparations with pre-existing QTc prolongation should include electrocardiographic monitoring as a safety endpoint.

Reproductive and Developmental Safety

Tadalafil, like other PDE5 inhibitors, has been evaluated in reproductive toxicology studies. At supratherapeutic doses in rodents (up to 400 mg/kg/day), no embryotoxic or teratogenic effects were identified. At lower doses, some studies have reported transient effects on sperm motility parameters, attributed to PDE5/PDE11 inhibition in the testes and epididymis. ^[4]

Researchers using reproductively intact animals in long-duration tadalafil treatment studies should consider including spermatological and hormone panel endpoints to characterize any gonadal effects at their specific dose level.

How It Compares

Tadalafil vs. Sildenafil, Research Selection Criteria

The choice between tadalafil and sildenafil as a research tool compound is primarily driven by the study design's temporal requirements and the downstream tissue of interest. Sildenafil's shorter half-life (approximately 4 hours) makes it the preferred agent for acute, single-dose mechanistic experiments where researchers want clean pharmacological on/off control between experimental sessions. Its higher aqueous solubility also simplifies intravenous administration in acute hemodynamic preparations where oral gavage is impractical. ^[3]

Tadalafil's 17.5-hour half-life is the better choice for chronic dosing models where sustained tonic PDE5 inhibition is the experimental goal, such as in prevention-of-fibrosis designs, chronic pulmonary hypertension regression models, or neuroprotection studies where weeks of treatment are required. The once-daily oral dosing made possible by the long half-life reduces animal handling stress compared to twice-daily or thrice-daily sildenafil dosing regimens. ^[11]

Sildenafil's lower PDE6 selectivity (approximately 10-fold vs. PDE5) is a relevant consideration in any study involving visual system, retinal physiology, or photoreceptor function endpoints. Tadalafil's 780-fold PDE6 selectivity essentially eliminates this confound for most experimental concentrations. ^[3]

Tadalafil vs. Vardenafil

Vardenafil has a slightly higher in-vitro potency than tadalafil (Ki approximately 0.7 nM vs. 0.94 nM for PDE5) but shares the short half-life limitation of sildenafil. Its lower oral bioavailability (approximately 15%) and significant food interaction make it logistically less practical in animal research designs. Vardenafil's near-absence of PDE11 activity (>1000-fold selective) makes it the preferred tool compound for experiments specifically trying to isolate PDE5-only effects from any PDE11-mediated background, particularly in reproductive or pituitary tissue preparations.

Tadalafil's Unique Research Position

Across the PDE5 inhibitor class, tadalafil occupies a distinct position: longest half-life by a substantial margin, highest oral bioavailability, food-independent absorption, and lowest PDE6 selectivity concerns balanced against the most significant PDE11 activity. For researchers studying chronic vascular remodeling, pulmonary hypertension regression, or endothelial adaptation biology, these pharmacokinetic features make tadalafil the most experimentally practical oral PDE5 inhibitor available. ^[7]

The Apollo Peptide Sciences 100-tablet pack at $1.00 per tablet also provides favorable economics for multi-group, long-duration animal studies where per-compound cost can escalate quickly. Researchers should compare this against their specific rodent dose requirements using the worked examples above to confirm that the pack size is appropriate for their planned protocol duration and group sizes.

Where to Buy

Apollo Peptide Sciences lists this product at /product/tadalafil-cialis-20mg-50pills, where the current pricing, availability, and any active promotions are maintained. The product page also links to batch-specific documentation including CoA data where available.

When evaluating any supplier for research-grade oral compounds, key selection criteria include: documentation of third-party analytical testing, clear statement of research-use-only terms, transparent lot traceability, and accessible customer service for technical queries. Our supplier selection guide provides a structured framework for evaluating these criteria across multiple vendors in the research peptide and small-molecule space.

For researchers purchasing tadalafil specifically, confirming that the CoA documents HPLC purity ≥98%, accurate tablet content uniformity, and absence of cytotoxic process impurities is the minimum acceptable standard before incorporating any lot into a formal research protocol.

The 100-tablet pack provides flexibility for multi-cohort studies. Researchers planning a single short-duration rat study at 5 mg/kg/day will consume approximately 20-25 tablets depending on the number of animals, leaving a reserve for pilot dose-finding or pharmacokinetic satellite groups. Proper storage at room temperature away from moisture and direct light is important for maintaining tablet integrity over the shelf life; unlike lyophilized peptides, tablets do not require cold-chain storage, but tablet coatings can degrade in humid environments.

See our full review of the Apollo Peptide Sciences tadalafil product for vendor-specific details, user documentation, and ordering information.

Open Research Questions

The tadalafil literature, while extensive, contains several areas where evidence is either contested, preliminary, or methodologically limited, presenting genuine research opportunities for investigators with appropriate laboratory capabilities.

Cardiac PDE5 Inhibition in Heart Failure

The hypothesis that tadalafil and other PDE5 inhibitors can improve outcomes in heart failure with preserved ejection fraction (HFpEF) remains unresolved. Early mechanistic studies in animal models of pressure-overload hypertrophy (including the Takimoto et al. work cited above) were promising. ^[14] However, the RELAX trial, a multicenter, randomized, double-blind, placebo-controlled study of sildenafil in HFpEF (n = 216, 24 weeks), found no significant improvement in peak oxygen consumption or 6MWD versus placebo. ^[9]

Whether tadalafil's distinct half-life profile and potentially different tissue exposure pattern would produce a different outcome in HFpEF remains untested in a large human trial. Preclinical mechanistic work has also been complicated by species differences in cardiac PDE5 expression between rodents and humans, and by the observation that PDE5 upregulation in failing human hearts may be regionally heterogeneous in ways that rodent TAC models do not capture. Researchers interested in this question have a well-defined opportunity to design mechanistic studies using human myocardial tissue preparations (ex-vivo) or iPSC-derived cardiomyocytes under hypertrophic stimulation conditions.

Neuroprotective and Cognitive Biology Applications

A growing body of in-vitro and rodent work has examined whether PDE5 inhibition can enhance hippocampal cGMP signaling and support synaptic plasticity or cognitive performance. cGMP acts as a second messenger in the hippocampal LTP (long-term potentiation) circuit through a NO-sGC-cGMP-PKG pathway, and PDE5 inhibition would theoretically sustain this signal. ^[6]

Rodent studies using Morris water maze and novel object recognition paradigms have reported improved spatial memory performance with tadalafil treatment in aged animals and in models of vascular dementia. ^[8] These findings are biologically plausible given hippocampal PDE5A expression, but the translational evidence base remains thin. Whether the doses achieving cognitive effects in rodents produce meaningful human CNS PDE5 inhibition at the plasma concentrations reached with standard oral doses is uncertain, given the blood-brain barrier's modest permeability to tadalafil.

Oncological Research

Several research groups have explored whether cGMP elevation through PDE5 inhibition can modulate tumor microenvironment immunosuppression, specifically by reducing myeloid-derived suppressor cell (MDSC) accumulation in the tumor stroma. MDSCs suppress T-cell-mediated anti-tumor immunity, and preclinical studies have found that sildenafil and tadalafil can reduce MDSC frequency and improve the efficacy of cancer immunotherapy in mouse tumor models. ^[13]

A pilot clinical study in head-and-neck squamous cell carcinoma patients reported reduced tumor-infiltrating MDSC frequency and enhanced T-cell responses with sildenafil at standard doses. Whether tadalafil produces equivalent or superior immunomodulatory effects (given its longer duration of action), and whether this mechanism is robust across tumor types, remains an active area of research with substantial uncertainty. Researchers entering this area should design carefully controlled immunophenotyping endpoints and account for the many non-PDE5 variables that influence MDSC biology in vivo.

Skeletal Muscle and Dystrophinopathy Research

Duchenne muscular dystrophy (DMD) is associated with nNOS (neuronal nitric oxide synthase) mislocalization from the sarcolemmal dystrophin-associated protein complex, leading to deficient cGMP signaling during exercise and consequent functional ischemia in contracting muscle. ^[8] PDE5 inhibition was hypothesized to compensate for reduced cGMP generation by slowing its breakdown. Mouse mdx model studies showed improved vascular responsiveness with tadalafil. However, a randomized clinical trial of tadalafil in boys with DMD (the ReSolve trial) did not meet its primary endpoint of ambulatory function, raising questions about whether the animal model effects translate to human disease. Understanding why this translation failed is itself an important research question. ^[8]

Pharmacological Context

The development of selective PDE5 inhibitors represents one of the more elegant applications of structure-based drug design in modern pharmacology. The recognition that penile erection required NO-mediated cGMP accumulation in cavernosal smooth muscle, combined with the identification of PDE5 as the dominant cGMP-degrading enzyme in that tissue, provided a mechanistically coherent target hypothesis that led directly to sildenafil's development and, subsequently, the structural optimization that produced tadalafil. ^[5]

What makes tadalafil pharmacologically distinct from its predecessors is not just potency or selectivity, but the structural features that account for its prolonged duration of action. The rate of dissociation from the PDE5 catalytic site (koff) is slower for tadalafil than for sildenafil or vardenafil, contributing to a longer functional inhibition period independent of plasma concentration. This residence-time effect, combined with the high plasma protein binding (94%) that creates a depot of slowly releasing free drug, collectively explain why the clinical duration of action (up to 36 hours) substantially exceeds what would be predicted from simple peak plasma concentration modeling. ^[2]

The NO-cGMP-PKG axis that tadalafil modulates sits at the intersection of multiple physiological regulatory systems: vascular tone, platelet aggregation, smooth muscle proliferation, cardiac contractility, and neural plasticity. This places tadalafil in an unusual position as a research tool - it is simultaneously highly specific (sub-nanomolar PDE5 affinity) and broadly physiologically relevant across organ systems that all rely on cGMP signaling. Researchers leveraging tadalafil in non-erectile research contexts benefit from this breadth, but must design controls that disambiguate target-mediated effects from systemic hemodynamic consequences of PDE5 inhibition. ^[7]

The concept of tonic versus phasic NO-cGMP signaling is also important for contextualizing tadalafil research. In most vascular beds, NO is released tonically by eNOS in endothelial cells in response to shear stress, maintaining a baseline vasodilatory tone. Tadalafil amplifies this tonic signal by preventing cGMP hydrolysis. In tissues where NO is released phasically (for example, in the corpus cavernosum where neural NO release occurs specifically during sexual stimulation, or in the gut where enteric neurons signal), tadalafil amplifies the phasic signal without a constitutive background. This distinction matters for research design because it means tadalafil's effects are stimulus-dependent in phasic-signaling tissues, which can produce the appearance of no effect in the absence of an appropriate triggering stimulus. ^[5]